Premed · Premed · Microbiology
Lecture 22: Antimicrobial Resistance
Microbiology
Learning Objectives
By the end of this lecture, students will be able to:
- Define antimicrobial resistance and distinguish intrinsic from acquired resistance
- Describe the major biochemical mechanisms of resistance: enzymatic inactivation, target modification, efflux pumps, and reduced permeability
- Explain how resistance genes are acquired and disseminated through horizontal gene transfer
- Describe the clinical significance of MRSA, VRE, ESBL-producing organisms, and carbapenem-resistant Enterobacterales
- Discuss the factors driving the antimicrobial resistance crisis
- Explain strategies for combating antimicrobial resistance including antimicrobial stewardship
Lecture Content
I. Overview and Definitions
Antimicrobial resistance (AMR) refers to the ability of a microorganism to survive and grow in the presence of an antimicrobial agent that would normally inhibit or kill it. AMR is fundamentally a natural phenomenon: bacteria have produced antibiotics and corresponding resistance mechanisms for millions of years, and a vast resistome exists among environmental bacteria. However, human overuse and misuse of antibiotics has dramatically accelerated the emergence and spread of clinically relevant resistance.
Resistance can be classified into two broad categories. Intrinsic resistance is inherent and chromosomally encoded, present in all members of a given species. For example, Mycoplasma species have no cell wall and are therefore intrinsically resistant to beta-lactams. Similarly, the outer membrane of Gram-negative bacteria excludes large molecules like vancomycin, and Enterococcus faecalis possesses low-affinity PBPs that confer intrinsic resistance to cephalosporins. Acquired resistance, by contrast, is gained through mutation or horizontal gene transfer and can arise in previously susceptible organisms. It is clinically more concerning because it is unpredictable and capable of spreading between organisms.
II. Biochemical Mechanisms of Resistance
A. Enzymatic Inactivation/Modification of the Drug
The most clinically important examples of enzymatic resistance involve the beta-lactamases, enzymes that hydrolyze the beta-lactam ring and render the drug inactive. Penicillinases are narrow-spectrum beta-lactamases that degrade penicillins, such as those encoded by the blaZ gene of S. aureus. Extended-spectrum beta-lactamases (ESBLs) can hydrolyze both penicillins and third-generation cephalosporins; the CTX-M, SHV, and TEM variants are commonly found in E. coli and Klebsiella pneumoniae. AmpC beta-lactamases are chromosomally encoded and often inducible in the SPICE organisms (Serratia, Providencia, indole-positive Proteus, Citrobacter, and Enterobacter) or may be plasmid-mediated; they resist cephalosporins and most beta-lactamase inhibitors except avibactam.
The carbapenemases represent the most alarming class, as they hydrolyze virtually all beta-lactams including carbapenems. KPC (Klebsiella pneumoniae carbapenemase) is a class A serine enzyme and the most common carbapenemase in the United States. NDM (New Delhi metallo-beta-lactamase) is a class B metallo-enzyme that requires zinc and has spread widely across the globe. OXA-48-like enzymes are class D beta-lactamases common in Europe and the Middle East. These enzymes are classified according to the Ambler molecular classification system (classes A, B, C, and D) based on amino acid sequence.
Beyond the beta-lactamases, aminoglycoside-modifying enzymes (AMEs) represent another major category of enzymatic inactivation. Acetyltransferases (AAC), phosphotransferases (APH), and nucleotidyltransferases (ANT) modify hydroxyl or amino groups on aminoglycoside molecules, preventing them from binding their ribosomal target. Chloramphenicol acetyltransferases (CAT) acetylate chloramphenicol so that it can no longer bind the 50S ribosomal subunit.
B. Target Site Modification
In this mechanism, alteration of the drug target reduces the binding affinity of the antimicrobial agent. MRSA (methicillin-resistant Staphylococcus aureus) provides a paradigmatic example: acquisition of the mecA gene, carried on the SCCmec mobile genetic element, encodes PBP2a, an alternative penicillin-binding protein with low affinity for all beta-lactam antibiotics. VRE (vancomycin-resistant Enterococcus) achieves resistance through the vanA or vanB gene clusters, which modify the peptidoglycan terminus from D-Ala-D-Ala to D-Ala-D-Lac, preventing vancomycin from binding.
Ribosomal methylation is mediated by erm genes encoding methylases that modify 23S rRNA, conferring cross-resistance to macrolides, lincosamides, and streptogramins B (the MLSB phenotype). Fluoroquinolone resistance typically arises through mutations in the gyrA and parC genes, which encode subunits of DNA gyrase and topoisomerase IV, respectively, reducing drug binding. Rifampin resistance results from mutations in the rpoB gene encoding the RNA polymerase beta subunit; because this is a single-step mutation, rifampin must always be used in combination therapy.
C. Efflux Pumps
Efflux pumps are membrane-spanning transport proteins that actively pump antibiotics out of the cell faster than they can accumulate intracellularly. The major facilitator superfamily (MFS) includes tetracycline-specific efflux pumps encoded by genes such as tetA, tetB, and tetK. The resistance-nodulation-division (RND) family is particularly important in Gram-negative bacteria; examples include the AcrAB-TolC system in E. coli and the MexAB-OprM system in P. aeruginosa, both of which can export multiple structurally diverse drug classes simultaneously. Additional efflux families include the MATE, SMR, and ABC transporter families. Because a single efflux pump may export many different drugs, these systems can confer multidrug resistance in a single genetic step.
D. Reduced Permeability
In Gram-negative bacteria, loss or modification of outer membrane porins can reduce antibiotic entry into the cell. Loss of the OprD porin in P. aeruginosa specifically confers carbapenem resistance because imipenem normally enters through this channel. Mutations in OmpK35 and OmpK36 in K. pneumoniae similarly reduce the entry of beta-lactam antibiotics. Reduced permeability often works synergistically with other resistance mechanisms, particularly efflux pumps, to produce clinically significant resistance.
E. Target Bypass/Overproduction
Target bypass involves the acquisition of an alternative enzyme that performs the same essential function as the original target but is insensitive to the drug. The PBP2a of MRSA functions as an alternative transpeptidase, and the VanA system provides an alternative D-Ala-D-Lac ligase. Target overproduction achieves resistance by increasing expression of the drug target to overwhelm the drug, as seen with thymidylate synthase overproduction conferring trimethoprim resistance.
<image>A four-panel diagram illustrating the major biochemical mechanisms of antimicrobial resistance. Panel A (Enzymatic inactivation): A beta-lactam antibiotic approaching a bacterial cell; a beta-lactamase enzyme on the periplasmic side cleaves the beta-lactam ring (before/after molecular structure shown); classification table listing penicillinases, ESBLs, AmpC, and carbapenemases (KPC, NDM, OXA-48). Panel B (Target modification): Comparison of a normal PBP binding penicillin versus PBP2a (MRSA) with low affinity; vancomycin binding D-Ala-D-Ala versus failing to bind D-Ala-D-Lac (VRE). Panel C (Efflux pumps): Cross-section of a Gram-negative cell showing the tripartite RND efflux system (AcrB inner membrane pump, AcrA periplasmic adaptor, TolC outer membrane channel) pumping multiple antibiotic types (tetracycline, fluoroquinolone, chloramphenicol) out of the cell. Panel D (Reduced permeability): Gram-negative outer membrane with normal porins allowing antibiotic entry (left) versus mutant/absent porins blocking entry (right); combined with efflux for synergistic resistance.</image>
III. Genetic Basis of Resistance Acquisition
Resistance genes can arise through spontaneous chromosomal mutations that are selected under antibiotic pressure. Point mutations in target genes such as gyrA, rpoB, or 23S rRNA directly alter drug targets, while regulatory mutations can lead to overexpression of efflux pumps or reduced porin expression. These mutations occur at a frequency of approximately 10^-6 to 10^-9 per cell division per gene.
Horizontal gene transfer (HGT) is the acquisition of resistance genes from other organisms and is the primary engine driving the spread of resistance in clinical settings. Conjugation, the transfer of plasmids (R plasmids) carrying resistance genes via pili, is the most clinically significant mechanism. Transduction involves bacteriophage-mediated transfer of resistance genes, while transformation involves the uptake of free DNA released from lysed cells.
Several types of mobile genetic elements facilitate the movement and accumulation of resistance determinants. Plasmids are self-replicating extrachromosomal DNA molecules that can carry multiple resistance genes simultaneously, enabling multidrug resistance. Transposons are "jumping genes" that move between plasmids and chromosomes and carry resistance genes flanked by insertion sequences. Integrons are gene capture systems equipped with a site-specific recombinase (integrase) that captures gene cassettes, often encoding resistance factors; they are commonly found in Gram-negative pathogens. Insertion sequences are simple transposable elements that can activate gene expression or disrupt genes. The SCCmec element is the staphylococcal cassette chromosome carrying mecA, with multiple types (I through XIII) described. Finally, pathogenicity islands and resistance islands are large chromosomal segments acquired by HGT that can carry both virulence and resistance determinants.
IV. Clinically Important Resistant Organisms
MRSA (methicillin-resistant S. aureus) encompasses both hospital-associated strains (HA-MRSA) and community-associated strains (CA-MRSA, which often carry the Panton-Valentine leukocidin toxin). Treatment options include vancomycin, daptomycin, linezolid, and TMP-SMX or doxycycline for CA-MRSA skin infections.
VRE (vancomycin-resistant Enterococcus) primarily involves E. faecium, which is inherently more resistant than E. faecalis. The vanA gene cluster confers high-level, inducible resistance that is transferable even to S. aureus, while vanB provides variable-level resistance. Treatment options include linezolid, daptomycin, and quinupristin-dalfopristin (effective against E. faecium only).
ESBL-producing Enterobacterales, particularly E. coli and K. pneumoniae harboring CTX-M, SHV, or TEM variants, are resistant to penicillins and cephalosporins. Carbapenems are the drugs of choice for serious ESBL infections, though the role of piperacillin-tazobactam remains debated.
Carbapenem-resistant Enterobacterales (CRE) producing KPC, NDM, or OXA-48 enzymes represent a CDC-designated "urgent threat." Treatment options are limited and include ceftazidime-avibactam (effective against KPC and OXA-48), meropenem-vaborbactam (effective against KPC), cefiderocol, polymyxins, and tigecycline.
Multidrug-resistant Pseudomonas aeruginosa combines intrinsic resistance mechanisms (efflux, low permeability, chromosomal AmpC) with acquired mechanisms to become extremely difficult to treat. Available agents include ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol, and polymyxins. MDR Acinetobacter baumannii is a hospital-associated pathogen that is often pan-resistant, with polymyxins sometimes serving as the last resort.
Drug-resistant tuberculosis presents a particularly challenging problem. MDR-TB is defined by resistance to both isoniazid and rifampin, while XDR-TB adds resistance to a fluoroquinolone and at least one injectable agent (or bedaquiline/linezolid in updated definitions). Treatment requires 9 to 20 months with second-line agents; the BPaL regimen (bedaquiline, pretomanid, and linezolid) has shown promise. Drug-resistant Neisseria gonorrhoeae has progressively developed resistance to sulfonamides, penicillin, tetracycline, and fluoroquinolones, with emerging resistance to azithromycin and ceftriaxone. Current guidelines recommend intramuscular ceftriaxone monotherapy.
<image>A "rogues' gallery" infographic of the most clinically significant resistant organisms. Six panels arranged in a grid, each with a microscopy image or stylized icon of the bacterium, its resistance mechanism, and treatment options. Panel 1: MRSA -- Gram-positive cocci in clusters; mecA/PBP2a; treatments listed. Panel 2: VRE -- Gram-positive cocci in chains; vanA modifying D-Ala-D-Ala to D-Ala-D-Lac; treatments listed. Panel 3: ESBL E. coli/Klebsiella -- Gram-negative rods; CTX-M enzyme cleaving cephalosporin; carbapenems as treatment. Panel 4: CRE -- KPC/NDM carbapenemase; limited options (ceftazidime-avibactam, polymyxins). Panel 5: MDR Pseudomonas -- Gram-negative rod with multiple efflux pumps and AmpC; ceftolozane-tazobactam. Panel 6: MDR-TB -- acid-fast bacilli; rpoB and katG mutations; BPaL regimen. A threat-level color bar (urgent, serious, concerning) from the CDC classification is shown.</image>
V. Drivers of the Resistance Crisis
Multiple interrelated factors fuel the global resistance crisis. Overuse and misuse in human medicine includes prescribing antibiotics for viral infections, employing unnecessary broad-spectrum therapy, debating the role of incomplete courses, and self-medication without prescription in many countries. Agricultural and veterinary use of antibiotics as growth promoters and prophylactics in livestock generates resistant organisms capable of transferring to humans through the food chain and the environment. Inadequate infection control in healthcare settings allows transmission of resistant organisms, compounded by poor hand hygiene compliance.
The "discovery void" in new drug development is particularly alarming: few truly novel antibiotic classes have been developed since the 1980s, largely because of pharmaceutical industry disinvestment driven by low return on investment. Global travel and trade enable rapid international dissemination of resistant clones, as demonstrated by the global spread of NDM-1 from South Asia. Inadequate sanitation and water treatment contribute to environmental contamination with antibiotics and resistant bacteria, particularly in low-income settings. Finally, biofilm formation allows bacteria to tolerate antibiotic concentrations 10 to 1000 times higher than those affecting planktonic cells, complicating the treatment of device-related infections.
VI. Strategies to Combat AMR
A. Antimicrobial Stewardship
Antimicrobial stewardship programs aim to optimize antibiotic prescribing by ensuring the right drug is given at the right dose for the right duration via the right route. Key strategies include de-escalation from broad-spectrum to narrow-spectrum agents based on culture results, prospective audit and feedback by stewardship teams, prior authorization requirements for restricted antibiotics, and the use of clinical decision support tools along with institutional antibiograms.
B. Infection Prevention and Control
Preventing transmission of resistant organisms requires rigorous hand hygiene, contact precautions, and isolation of patients colonized or infected with MDR organisms. Environmental decontamination using ultraviolet light or hydrogen peroxide vapor reduces surface contamination. Screening and active surveillance cultures allow early identification of carriers, and care bundles targeting device-related infections (central lines, urinary catheters, and ventilators) reduce opportunities for resistant organisms to gain a foothold.
C. Diagnostic Innovation
Rapid diagnostic technologies such as PCR, MALDI-TOF mass spectrometry, and whole-genome sequencing enable faster identification of pathogens and their resistance profiles, allowing clinicians to initiate targeted therapy sooner and discontinue unnecessary broad-spectrum coverage. Point-of-care tests that distinguish bacterial from viral infections can reduce unnecessary antibiotic prescribing at the initial encounter.
D. Novel Therapeutic Approaches
Several innovative strategies are under development or have recently entered clinical practice. New antibiotics include siderophore cephalosporins such as cefiderocol and novel beta-lactamase inhibitors including avibactam, vaborbactam, and relebactam. Phage therapy has experienced renewed interest for treating MDR infections that have exhausted conventional options. Anti-virulence strategies aim to disarm pathogens without killing them, theoretically reducing the selective pressure for resistance. Antibody-based therapies, exemplified by bezlotoxumab against C. difficile toxin B, offer pathogen-specific approaches. Microbiome restoration through fecal microbiota transplantation and defined bacterial consortia (such as SER-109 for recurrent C. difficile) addresses the dysbiosis that facilitates resistant infections. Emerging technologies include antimicrobial peptides, CRISPR-based antimicrobials that enable targeted killing of resistant bacteria, and bacteriophage-derived lysins.
E. Global and Policy Initiatives
The WHO Global Action Plan on AMR (2015) established a framework for international cooperation, while the CDC Antibiotic Resistance Threats Report, updated periodically, prioritizes resistant organisms by threat level. The One Health approach integrates human, animal, and environmental health strategies. Organizations such as GARDP (Global Antibiotic Research and Development Partnership) and CARB-X fund new antibiotic development. Incentive models to encourage pharmaceutical investment include push mechanisms (grants for research and development) and pull mechanisms (market entry rewards and subscription models such as the UK "Netflix" model for antibiotics).
